Penicillins

New study by WHO Europe and ECDC examines variations in antibiotic consumption in European countries between 2014 and 2018

Retrieved on: 
Wednesday, July 7, 2021
Branches of biology, Health sciences, Health, Penicillins, Cephalosporin, Enones, Antibiotic, Antimicrobial, Consumption, American Motors Corporation

The study focuses on data from 30 EU/EEA countries of the European Surveillance of Antibiotic Consumption Network (ESAC-Net) and 15 countries of the WHO Europe Antimicrobial Medicines Consumption (AMC) Network, and aimed at examining the total consumption and patterns of consumption of antibiotics, i.e.

Key Points: 
  • The study focuses on data from 30 EU/EEA countries of the European Surveillance of Antibiotic Consumption Network (ESAC-Net) and 15 countries of the WHO Europe Antimicrobial Medicines Consumption (AMC) Network, and aimed at examining the total consumption and patterns of consumption of antibiotics, i.e.
  • However, there were considerable differences in the consumption of various antibiotic groups, with a larger consumption of penicillins and tetracyclines and a lower consumption of cephalosporins and quinolones in ESAC-Net countries than in WHO Europe AMC Network countries.
  • For the 15 WHO Europe AMC Network countries, parenteral formulations comprised between 2.8% and 40.1% of total consumption.
  • Furthermore, Access antibiotics represented more than 60% of total consumption in 17 of 29 ESAC-Net countries, and three of 15 WHO Europe AMC Network countries.

TBD Media Group's New Campaign Gives a Platform to the Leaders at this Pivotal Moment of Business and Society

Retrieved on: 
Thursday, June 17, 2021
Aviation, Aviators, Branches of biology, Fellows of the Royal Society, Penicillins, Penicillium, Microbiology, Secondary metabolites, Alexander Fleming, Antibiotic, Fleming, Wright brothers

LONDON, June 17, 2021 /PRNewswire/ --TBD Media Group announces the launch of a brand-new and ground-shaking new documentary series: 50 Global Leaders.

Key Points: 
  • LONDON, June 17, 2021 /PRNewswire/ --TBD Media Group announces the launch of a brand-new and ground-shaking new documentary series: 50 Global Leaders.
  • Throughout history there have been pivotal moments that changed society, unlocked new potential, and altered the world as we knew it thereafter.
  • In 1903, the Wright Brothers achieved the first airplane flight, claiming the skies for personal and commercial travel.
  • In 1928, Doctor Alexander Fleming discovered Penicillin, paving the way for research into antibiotics and revolutionising how we use medicine.

TBD Media Group's New Campaign Gives a Platform to the Leaders at this Pivotal Moment of Business and Society

Retrieved on: 
Thursday, June 17, 2021
Aviation, Aviators, Branches of biology, Fellows of the Royal Society, Penicillins, Penicillium, Microbiology, Secondary metabolites, Alexander Fleming, Antibiotic, Fleming, Wright brothers

LONDON, June 17, 2021 /PRNewswire/ --TBD Media Group announces the launch of a brand-new and ground-shaking new documentary series: 50 Global Leaders.

Key Points: 
  • LONDON, June 17, 2021 /PRNewswire/ --TBD Media Group announces the launch of a brand-new and ground-shaking new documentary series: 50 Global Leaders.
  • Throughout history there have been pivotal moments that changed society, unlocked new potential, and altered the world as we knew it thereafter.
  • In 1903, the Wright Brothers achieved the first airplane flight, claiming the skies for personal and commercial travel.
  • In 1928, Doctor Alexander Fleming discovered Penicillin, paving the way for research into antibiotics and revolutionising how we use medicine.

Qpex Biopharma Initiates Phase 1 Study of ORAvance™ for Oral Treatment of Drug-Resistant Gram-Negative Bacterial Infections

Retrieved on: 
Wednesday, May 12, 2021
Biotechnology, Infectious diseases, Health, Pharmaceutical, Clinical trials, Beta-lactam antibiotics, β-lactam antibiotic, β-Lactamase inhibitor, Beta-lactamase, Biomedical Advanced Research and Development Authority, Beta-lactamase inhibitors, Antibiotics, Biocides, Drugs, Infectious diseases, Penicillins

The World Health Organization (WHO) has also prioritized development of new treatments for these pathogens.

Key Points: 
  • The World Health Organization (WHO) has also prioritized development of new treatments for these pathogens.
  • Two of the products use QPX7728, an ultra-broad-spectrum beta-lactamase inhibitor that restores the potency of beta-lactam antibiotics in vitro and in vivo.
  • Qpex\xe2\x80\x99s current collaboration with BARDA is focused on advancing a portfolio of novel antibiotics, including the QPX7728-based products OMNIvance and ORAvance.
  • For more information, please visit www.qpexbio.com and follow us on Twitter and LinkedIn .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512005284/en/\n'

North America Antibiotics Market Report 2021: Action Mechanism, Drug Class, Country, Industry Analysis and Forecast, 2020 - 2026 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, February 16, 2021
Health, Pharmaceutical, Branches of biology, Health sciences, Health, Hepatotoxins, Penicillins, Antibiotic, Antimicrobial resistance, Antibiotic use in livestock

The "North America Antibiotics Market By Action Mechanism, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "North America Antibiotics Market By Action Mechanism, By Drug Class, By Country, Industry Analysis and Forecast, 2020 - 2026" report has been added to ResearchAndMarkets.com's offering.
  • With the discovery of the antibiotic penicillin in 1920, many antibiotic compounds have been utilized to cure various bacterial infections.
  • The development of unique approaches for advanced antibiotics for curing bacterial infections and numerous clinical trials drives the global antibiotics market.
  • Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

Transplant Patients with a Penicillin Allergy Label Experience a Higher Rate of Adverse Effects When Using Non-Penicillin Antibiotics

Retrieved on: 
Tuesday, February 16, 2021
Branches of biology, Penicillins, Microbiology, Scottish inventions, Secondary metabolites, Drugs, Health care, Penicillium, Side effects of penicillin, Antibiotic, Drug resistance, Antibiotic use in dentistry

Since individuals with a penicillin allergy label are given alternative antibiotic regimens, the researchers aimed to investigate if transplant patients with a penicillin allergy label would have worse outcomes from receiving alternative regimens.

Key Points: 
  • Since individuals with a penicillin allergy label are given alternative antibiotic regimens, the researchers aimed to investigate if transplant patients with a penicillin allergy label would have worse outcomes from receiving alternative regimens.
  • A retrospective analysis was done to compare outcomes between these patients to transplant patients treated for the same infections who did not have a penicillin allergy label.
  • Compared to the control group, transplant patients with the penicillin allergy label had a higher rate of adverse effects from non-penicillin antibiotics (8.9% compared to 6.3%).
  • The transplant patients with a penicillin allergy label also had a lower rate of infection with multi-drug resistant organisms (0.3% compared to 1%).

Centrient Pharmaceuticals to acquire Astral SteriTech, expanding its product portfolio with sterile injectable antibiotic finished dosage forms

Retrieved on: 
Monday, February 15, 2021
Chemical compounds, Organic compounds, Penicillins, Branches of biology, Microbiology, Penicillium, Cephalosporin, β-lactam antibiotic, Beta-lactam, Antibiotic, Production of antibiotics

The products offered by Astral SteriTech are sterile injectable finished dosage forms for Semi-Synthetic Cephalosporins and Semi-Synthetic Penicillins.

Key Points: 
  • The products offered by Astral SteriTech are sterile injectable finished dosage forms for Semi-Synthetic Cephalosporins and Semi-Synthetic Penicillins.
  • Being close to Centrients core products of beta-lactam antibiotics, the acquired product portfolio provides Centrient a diversification opportunity within the attractive growing niche segment of sterile injectable antibiotics.
  • With the broadened product portfolio, Centrient can further meet the needs of its customers in Semi-Synthetic Cephalosporin and Semi-Synthetic Penicillin finished dosage forms and become the preferred partner in these segments.
  • Astral SteriTech is a leading international contract manufacturer specialized in sterile antibiotic powder injectable finished dosage forms.

Amoxicillin (CAS 61336-70-7) Market Research Report 2020 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 24, 2020
Health, Pharmaceutical, Amoxicillin, Lyme disease, Penicillins, Phenols, RTT, Market research, Chemistry, Physical sciences, Health

The "Amoxicillin (CAS 61336-70-7) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Amoxicillin (CAS 61336-70-7) Market Research Report 2020" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of amoxicillin.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The amoxicillin global market report key points:

Allecra Therapeutics Announces Positive Top-Line Results for Phase 3 ALLIUM Clinical Trial of EXBLIFEP® for Complicated Urinary Tract Infections

Retrieved on: 
Tuesday, February 25, 2020
Medical specialties, Medicine, Health, Infectious diseases, Penicillins, Beta-lactamase inhibitors, Diketopiperazines, Piperacillin, Wyeth, Tazobactam, Hospital-acquired infection, Urinary tract infection

Overall success was 79.1% for EXBLIFEP vs. 58.9% for piperacillin-tazobactam (adjusted stratified difference, 21.2% [95% stratified Newcombe CI, 14.3% to 27.9%]).

Key Points: 
  • Overall success was 79.1% for EXBLIFEP vs. 58.9% for piperacillin-tazobactam (adjusted stratified difference, 21.2% [95% stratified Newcombe CI, 14.3% to 27.9%]).
  • Treatment discontinuations were seen at comparable levels in 5.2% and 4.0% in EXBLIFEP and piperacillin-tazobactam respectively.
  • HAP is the second most common nosocomial infection (after urinary tract infections) and accounts for 1520% of the total.
  • Allecra is supported by Forbion, Andera Partners, Delos Capital, Xeraya Capital, EMBL Ventures, and BioMed Partners.

BioCryst to Provide Berotralstat and BCX9930 Program Updates at 38th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Sunday, January 12, 2020
RTT, Drugs, Penicillins, Complement deficiency, Medical specialties, Organ systems, BioCryst Pharmaceuticals, Amoxicillin, Hereditary angioedema, Clavulanic acid, Angioedema

RESEARCH TRIANGLE PARK, N.C., Jan. 12, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will provide updates on berotralstat, an oral kallikrein inhibitor for hereditary angioedema (HAE), and BCX9930, an oral Factor D inhibitor for complement-mediated diseases, this week at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Jan. 12, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will provide updates on berotralstat, an oral kallikrein inhibitor for hereditary angioedema (HAE), and BCX9930, an oral Factor D inhibitor for complement-mediated diseases, this week at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco.
  • BioCryst is positioned for transformation in 2020 with multiple global approvals and launches of berotralstat, and PNH proof of concept data with BCX9930.
  • Healthy volunteers in the MAD cohorts were prophylactically dosed with the broad-spectrum antibiotic, amoxicillin/clavulanate.
  • BCX9930 was safe and generally well tolerated at all doses studied in single ascending dose and MAD cohorts.